Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (ORGO) is a leader in regenerative medicine, specializing in advanced wound care and surgical biologics. This page aggregates all official company announcements, press releases, and material developments for investors and industry observers.
Find updates on quarterly earnings, product innovations, regulatory milestones, and clinical trial progress. Our curated feed ensures timely access to information affecting ORGO's position in regenerative therapies and sports medicine markets.
Key areas include bioactive wound care solutions, FDA filings, partnership announcements, and manufacturing updates. All content is sourced directly from company communications to maintain accuracy and compliance.
Bookmark this page for easy access to Organogenesis' latest developments. Check back regularly for updates on their pioneering work in tissue repair technologies and healthcare market strategies.
Organogenesis Holdings (Nasdaq: ORGO), a leading regenerative medicine company, has announced it will report its second quarter fiscal year 2024 financial results on August 8, 2024, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a corporate update. Interested parties can access the live webcast or dial (800) 715-9871 with access code 6679912 to participate. The webcast will also be available on the company's investor relations website and archived for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine leader in advanced wound care and surgical sports medicine, announced its participation in the Truist Securities MedTech Conference on June 18, 2024, in Boston, MA. The company's management team will engage in one-on-one meetings but will not deliver a formal presentation.
Organogenesis Holdings Inc. reported a strong start to 2024 with net revenue of $110.0 million, an increase of $2.3 million compared to the first quarter of 2023. Despite a net loss of $2.1 million, the company is confident in its market leadership and growth opportunities. The company's financials show a mix of positive and negative indicators, with an increase in revenue for Advanced Wound Care products and a decrease for Surgical & Sports Medicine products. Adjusted EBITDA decreased by $1.2 million, but the company remains optimistic about its expansion opportunities in new markets.
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee OA patients, including the most severe cases. The company plans to request an FDA meeting for a Biologics License Application filing.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
